Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)

Market Cap	14.71B +2.3%
Revenue (ttm)	3.04B +47.0%
Net Income	1.24B
EPS	0.61
Shares Out	1.96B
PE Ratio	12.40
Forward PE	22.79
Dividend	0.30 (3.92%)
Ex-Dividend Date	Jun 5, 2026

Volume	20,788,497
Open	7.70
Previous Close	7.66
Day's Range	7.45 - 7.73
52-Week Range	7.47 - 10.67
Beta	0.17
Analysts	Buy
Price Target	9.72 (+29.26%)
Earnings Date	Aug 24, 2026

About SHA:600867

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, it offers chemical drugs, such as repaglinide, sitagliptin phosphate, and metfor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 3,354
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600867

Analyst Summary

According to 4 analysts, the average rating for 600867 stock is "Buy." The 12-month stock price target is ¥9.72, which is an increase of 29.26% from the latest price.

Price Target

¥9.72

(29.26% upside)

Analyst Consensus: Buy